Supplementary Table S2 from Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors
Clare F. Malone(Broad Institute), Kimberly Stegmaier(Broad Institute), John M. Hatcher(Harvard University), Amy Saur Conway(Dana-Farber Cancer Institute), Delan Khalid(Dana-Farber Cancer Institute), Nathanael S. Gray(Stanford University), Gabriela Alexe(Broad Institute), Amanda L. Robichaud(Dana-Farber Cancer Institute), Alexandra B. Forman(Broad Institute), Amy Goodale(Broad Institute), Kathleen Engel(Broad Institute), Minjee Kim(Massachusetts Eye and Ear Infirmary), Federica Piccioni(Broad Institute), Allen Thayakumar(Dana-Farber Cancer Institute), Ashleigh Meyer(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
A Landscape of Pharmacogenomic Interactions in Cancer
|Cell|2016|2.3k
An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1
|Journal of Biological Chemistry|2009|1.8k
The promise and peril of chemical probes
|Nature Chemical Biology|2015|848
Genomic Copy Number Dictates a Gene-Independent Cell Response to CRISPR/Cas9 Targeting
|Cancer Discovery|2016|632